355
Views
1
CrossRef citations to date
0
Altmetric
HEMATOLOGICAL MALIGNANCY

SDF-1/CXCR4 signal is involved in decreased expression of p57kip2 in de novo MDS patients

, , , , &
Pages 220-228 | Published online: 18 Jul 2013
 

Abstract

P57kip2 is considered as a candidate tumor suppressor gene involvement in cell cycle control. In this study, we explored the expression of p57kip2 in various myelodysplastic syndrome (MDS) subsets by real-time quantitative PCR, as well as the relationship between p57kip2 and CXC receptor 4 (CXCR4). We also searched the role of stromal cell-derived factor-1 (SDF-1)/CXCR4 signal in p57kip2 expression in vitro. The expression of p57kip2 decreased in MDS cases (low grade MDS, P<0··001, n = 46; high grade MDS, P<0··001, n = 21), compared with that in control group. Patients with poor karyotype (according to IPSS) had lower p57kip2 than that in the normal group (P<0··05). P57kip2 expression increased after treatment with decitabine in the cases that had achieved response (P = 0··009, n = 7). Additionally, a positive correlation between p57kip2 and CXCR4 was investigated (r = 0··652, P<0··001, n = 67). P57kip2 expression in bone marrow mononuclear cells of normal controls increased significantly when co-cultured with SDF-1 in vitro, which could be blocked by AMD3100, whereas SDF-1 only induced a mild increase in p57kip2 in MDS. In conclusion, low expression of p57kip2 is common in MDS, which may play an important role in MDS pathogenesis. Reduced response to SDF-1 contributed to low expression of p57kip2 in MDS cases.

Acknowledgements

This study was supported in part by the National Nature science foundation of China (Grant No. NNSFC81170463).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.